Shared on15 Aug 25
Owens & Minor's price target was maintained at $6.28 as weak Q2 results and the potential divestiture of its hospital distribution business drove concerns about near-term performance and revenue outlook, although some analysts note Patient Direct strength and believe the recent selloff may be overdone. Analyst Commentary Recent Q2 results and updated outlook were disappointing, leading to reduced price targets and concerns about near-term performance.